Concepedia

The treatment of pulmonary<i>Wangiella dermatitidis</i>infection with oral voriconazole

Marilyn N. Bulloch

Journal of Clinical Pharmacy and Therapeutics · 2010 · 15 citations · 14 references

DOI

Abstract

Voriconazole appears to be effective as monotherapy for the treatment of pulmonary W. dermatitidis infections. A minimum of 3-4 months of antifungal treatment should be given. Adverse effects with prolonged voriconazole use do not appear to be a barrier to treatment.

References

14

Voriconazole Treatment for Less‐Common, Emerging, or Refractory Fungal Infections

John R. Perfect, Kieren A. Marr, Thomas J. Walsh et al. · Clinical Infectious Diseases · 2003 · 674 citations · Full text

, , +13

Spectrum of Clinically Relevant<i>Exophiala</i>Species in the United States

Jianhua Zeng, Deanna A. Sutton, Annette W. Fothergill et al. · Journal of Clinical Microbiology · 2007 · 233 citations · Full text

In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens

Sarah A. Radford, Elizabeth M. Johnson, David W. Warnock · Antimicrobial Agents and Chemotherapy · 1997 · 190 citations · Full text

, , +11

The neurotropic black yeast Exophiala dermatitidis has a possible origin in the tropical rain forest

Montarop Sudhadham, S. Prakitsin, Somsak Sivichai et al. · Studies in Mycology · 2008 · 141 citations · Full text

, , +15

Activities of voriconazole, itraconazole and amphotericin B in vitro against 590 moulds from 323 patients in the voriconazole Phase III clinical studies

Ana Espinel-Ingroff, Elizabeth M. Johnson, Hans P. Hockey et al. · Journal of Antimicrobial Chemotherapy · 2008 · 97 citations · Full text